The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: Cost-effectiveness analysis in France

European Journal of Health Economics

Volumn 15, Issue 8, 2014, Pages 791-800

  Touchon, Jacques ^a   Lachaine, Jean ^b   Beauchemin, Catherine ^b   Granghaud, Anna ^c   Rive, Benoit ^c   Bineau, Sébastien ^c  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Lundbeck   (France)

Author keywords

Alzheimer s disease; Cholinesterase inhibitors; Cost effectiveness; Memantine; Nursing home admission

Indexed keywords

EID: 84881067454     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0523-y     Document Type: Article

References (41)

1. Alzheimer’s Disease Education & Referral (ADEAR) Center: Alzheimer’s Disease NIH Publication No. 11-6423. http://www.nia.nih.gov/Alzheimers/Publications/adfact.htm (2011). Accessed Sept 2011
2. Jorm, A.F., Jolley, D.: The incidence of dementia: a meta-analysis. Neurology 51(3), 728–733 (1998)
3. Alzheimer’s Disease International: World Alzheimer Report. http://www.alz.co.uk/research/world-report (2009). Accessed Feb 2012
4. Letenneur, L., Commenges, D., Dartigues, J.F., Barberger-Gateau, P.: Incidence of dementia and Alzheimer’s disease in elderly community residents of south-western France. Int. J. Epidemiol. 23(6), 1256–1261 (1994)
5. European Commission Health and Consumers Directorate-General—Directorate C—Public Health and Risk Assessment: estimated number of people with dementia. http://ec.europa.eu/health/ph_information/dissemination/echi/docs/dementia2_en.pdf (2006). Accessed Jan 2012
6. Wimo, A., Jonsson, L., Gustavsson, A., McDaid, D., Ersek, K., Georges, J., Gulacsi, L., Karpati, K., Kenigsberg, P., Valtonen, H.: The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry (2011). doi:10.1002/gps.2610
7. Luengo-Fernandez, R., Leal, J., Gray, A.M.: Cost of dementia in the pre-enlargement countries of the European union. J. Alzheimers. Dis. 27(1), 187–196 (2011)
8. Rolland, Y., Andrieu, S., Crochard, A., Goni, S., Hein, C., Vellas, B.: Psychotropic drug consumption at admission and discharge of nursing home residents. J. Am. Med. Dir. Assoc. 13, 407.e7–407.e12 (2012)
9. Lopez, O.L., Becker, J.T., Wahed, A.S., Saxton, J., Sweet, R.A., Wolk, D.A., Klunk, W., Dekosky, S.T.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80(6), 600–607 (2009). doi:10.1136/jnnp.2008.158964
10. Yaffe, K., Fox, P., Newcomer, R., Sands, L., Lindquist, K., Dane, K., Covinsky, K.E.: Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287(16), 2090–2097 (2002)
11. Gaugler, J.E., Yu, F., Krichbaum, K., Wyman, J.F.: Predictors of nursing home admission for persons with dementia. Med. Care 47(2), 191–198 (2009). doi:10.1097/MLR.0b013e31818457ce
12. Birks, J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev(1), CD005593 (2006). doi:10.1002/14651858.CD005593
13. McKeage, K.: Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs 23(10), 881–897 (2009)
14. Danysz, W., Parsons, C.G., Mobius, H.J., Stoffler, A., Quack, G.: Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease—a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2(2–3), 85–97 (2000)
15. Wilkinson, D.: A review of the effects of memantine on clinical progression in Alzheimer’s disease. Int. J. Geriatr. Psychiatry (2011). doi:10.1002/gps.2788
16. Winblad, B., Poritis, N.: Memantine in severe dementia: results of the 9 M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14(2), 135–146 (1999)
17. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H.: Memantine Study Group: memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348(14), 1333–1341 (2003)
18. Winblad, B., Jones, R.W., Wirth, Y., Stoffler, A., Mobius, H.J.: Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement. Geriatr. Cogn. Disord. 24(1), 20–27 (2007). doi:10.1159/000102568
19. Gauthier, S., Loft, H., Cummings, J.: Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry 23(5), 537–545 (2008). doi:10.1002/gps.1949
20. Tariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3), 317–324 (2004). doi:10.1001/jama.291.3.317
21. Wimo, A., Winblad, B., Stoffler, A., Wirth, Y., Mobius, H.J.: Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 21(5), 327–340 (2003)
22. Caro, J.J., Getsios, D., Migliaccio-Walle, K., Raggio, G., Ward, A.: Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care. Neurology 57(6), 964–971 (2001)
23. Getsios, D., Caro, J.J., Caro, G., Ishak, K.: Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology 57(6), 972–978 (2001)
24. Lachaine, J., Beauchemin, C., Legault, M., Bineau, S.: Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can. J. Psychiatry 56(10), 596–604 (2011)
25. Collège des Economistes de la Santé (CES): Guide méthodologique pour l’évaluation économique des stratégies de santé. In. (2003)
26. Rolland, Y., Andrieu, S., Crochard, A., Goni, S., Hein, C., Vellas, B.: Psychotropic drug consumption at admission and discharge of nursing home residents. J. Am. Med. Dir. Assoc. (2011). doi:10.1016/j.jamda.2011.12.056
27. Mortality tables TH00-02 and TF00-02 calculated from INSEE data (mortality table 2000-2002). http://www.spac-actuaires.fr/jdd/public/documents/xls/TH-TF%2000-02.xls. Accessed May 2013
28. Neumann, P.J., Kuntz, K.M., Leon, J., Araki, S.S., Hermann, R.C., Hsu, M.A., Weinstein, M.C.: Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med. Care 37(1), 27–32 (1999)
29. Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNMATS): Medications price list. (November 2009)
30. Gallez et al.: Parliamentary report on Alzheimer’s disease and related diseases. (2005)
31. NICE technology appraisal guidance 111: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease—p. 31. In, vol. November 2011. (November 2006, amended August 2009)
32. Weycker, D., Taneja, C., Edelsberg, J., Erder, M.H., Schmitt, F.A., Setyawan, J., Oster, G.: Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr. Med. Res. Opin. 23(5), 1187–1197 (2007). doi:10.1185/030079907X188071
33. Loveman, E., Green, C., Kirby, J., Takeda, A., Picot, J., Payne, E., Clegg, A.: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol. Assess. 10(1), iii–iv, ix–xi, 1–160 (2006)
34. Getsios, D., Migliaccio-Walle, K., Caro, J.J.: NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 25(12), 997–1006 (2007)
35. Borah, B., Sacco, P., Zarotsky, V.: Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr. Med. Res. Opin. 26(8), 1957–1965 (2010). doi:10.1185/03007995.2010.493788
36. Helmer, C., Joly, P., Letenneur, L., Commenges, D., Dartigues, J.F.: Mortality with dementia: results from a French prospective community-based cohort. Am. J. Epidemiol. 154(7), 642–648 (2001)
37. Karlawish, J.H., Klocinski, J.L., Merz, J., Clark, C.M., Asch, D.A.: Caregivers’ preferences for the treatment of patients with Alzheimer’s disease. Neurology 55(7), 1008–1014 (2000)
38. Geldmacher, D.S., Provenzano, G., McRae, T., Mastey, V., Ieni, J.R.: Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J. Am. Geriatr. Soc. 51(7), 937–944 (2003)
39. Tariot, P.N.: Contemporary issues in the treatment of Alzheimer’s disease: tangible benefits of current therapies. J. Clin. Psychiatry 67(Suppl 3), 15–22; quiz 23 (2006)
40. ‘Plan Alzheimer 2008–2012’, France. (2008). http://www.plan-alzheimer.gouv.fr/ (2013). Accessed May 2013
41. Heinen-Kammerer, T., Rulhoff, H., Nelles, S., Rychlik, R.: Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer’s disease. Clin. Drug Investig. 26(6), 303–314 (2006)